Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | CASP6 | P55212 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | MMP14 | P50281 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | NQO2 | P16083 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11600917 | 0.84 | — | — | |
| SCHEMBL5112829 | 0.78 | ESR2 (0.39) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL9941977 | 0.77 | MEN1 (0.40) | KEAP1NFE2L2KMT2APOLBMEN1 | |
| SCHEMBL30361763 | 0.76 | PDPK1 (0.42) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL1651160 | 0.76 | PDPK1 (0.42) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL6676223 | 0.76 | CRHBP (0.40) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL29864580 | 0.76 | TDP1 (0.38) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL5066814 | 0.76 | TDP1 (0.38) | CRHBPCRHR2KEAP1NFE2L2ATM | |
| SCHEMBL31097097 | 0.76 | NQO2 (0.33) | MAPTNQO2ACHE | |
| SCHEMBL5455267 | 0.74 | KDM4E (0.38) | KMT2APOLBMEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-08-16 | — | — | US | disclosed |
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-08-16 | — | — | US | disclosed |
| US-20050153961-A1 | 1, 2, 4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents | LEE WILLIAM W (US) | 2005-07-14 | — | — | US | disclosed |
| US-6828321-B2 | Compounds specifically radiosensitize hypoxic tumor cells | SRI INTERNATIONAL | 2004-12-07 | — | — | US | disclosed |
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | disclosed |
| EP-0972517-B1 | Use of 1,2,4-benzotriazine oxides for the preparation of a medicament for the treatment of tumors | UNIV LELAND STANFORD JUNIOR (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2004026846-A1 | DNA-TARGETED BENZOTRIAZINE 1,4-DIOXIDES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-04-01 | — | — | WO | disclosed |
| US-20020103200-A1 | 1,2,4-Benzotriazine oxides as radiosensitizers and selective cytotoxic agents | LEE WILLIAM W (US) | 2002-08-01 | — | — | US | disclosed |
| US-6362184-B1 | KILLING TUMOR CELLS | SRI INTERNATIONAL | 2002-03-26 | — | — | US | disclosed |
| US-5484612-A | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1996-01-16 | — | — | US | disclosed |
| EP-0649658-A1 | Method of tumor treatment | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5175287-A | Lower alkyl nitrite under reductive deamination | S R I INTERNATIONAL (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0478545-A4 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | STANFORD RES INST INT (US) | 1992-08-05 | — | — | EP | disclosed |
| EP-0478545-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1992-04-08 | — | — | EP | disclosed |
| WO-1991004028-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1991-04-04 | — | — | WO | disclosed |
| EP-0413706-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1991-02-27 | — | — | EP | disclosed |
| WO-1989008647-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1989-09-21 | — | — | WO | disclosed |
| WO-1988002366-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1988-04-07 | — | — | WO | disclosed |
| US-4067981-A | FUNGICIDES, BACTERICIDES, INSECTICIDES, ACARICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103200-A1 | 1,2,4-Benzotriazine oxides as radiosensitizers and selective cytotoxic agents | HYOU1, HIF1AN, HIF1A | CRHBP 4760/4885CRHR2 4293/4885KEAP1 1023/4885 |
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | HIF1AN, HIF1A, HYOU1 | CRHBP 4360/4885CRHR2 3444/4885KEAP1 199/4885 |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | NPM1, DUOX1, NOX5 | CRHBP 4700/4885CRHR2 3115/4885KEAP1 412/4885 |
| US-20050153961-A1 | 1, 2, 4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents | HYOU1, HIF1AN, HIF1A | CRHBP 4760/4885CRHR2 4293/4885KEAP1 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.